In a recent publication of our first case with recurrent glioblastoma treated with allogeneic DC vaccination [30], we highlighted the decisive role of CD4+T-cells, and to a lesser extent CD8+T-cells, during the responsive phase, and treatment failure due to a shift in the immune response to a Th17 response pattern. This evidence concerns the gene CD8A and glioblastoma.